8-K/AFinancial Events

QUEST DIAGNOSTICS INC 8-K/A Report, Exit or Disposal Costs (Jul 11, 2006)

Filed July 11, 2006For Securities:DGX

Summary

This 8-K filing is an amendment to a previous report, providing updated financial details regarding Quest Diagnostics Incorporated's (DGX) decision to discontinue the operations of Nichols Institute Diagnostics (NID). The company is now estimating pretax charges for this exit activity to be between $32 million and $39 million, a reduction from the initial estimate of up to $45 million. These charges encompass the write-off of inventories, impairment of assets, employee termination benefits, contract termination costs, and expenses related to winding down the business. While the total pretax charges have been revised downwards, investors should note the significant cash expenditures estimated between $20 million and $27 million before tax benefits. The company also anticipates that a portion of these charges may not be tax-deductible, impacting net income.

Key Highlights

  • 1Quest Diagnostics (DGX) filed an amendment (8-K/A) on July 11, 2006, providing updated information on the discontinuation of Nichols Institute Diagnostics (NID).
  • 2The estimated pretax charges for discontinuing NID operations are now projected to be between $32 million and $39 million.
  • 3This revised estimate is lower than the initial estimate of up to $45 million disclosed in the prior 8-K filing.
  • 4Charges include $12 million for inventory write-offs and asset impairment, $5-6 million for employee termination, $8-12 million for contract terminations, and $7-9 million for wind-down support.
  • 5Estimated cash expenditures before tax benefits are between $20 million and $27 million.
  • 6Approximately $7-10 million of the charges are expected to be non-deductible for tax purposes, impacting net income.
  • 7The charges will be recorded primarily in the second quarter ($27-29 million) with the remainder in the third quarter.

Frequently Asked Questions

This filing is an amendment to a previous 8-K report, providing updated and refined financial estimates related to Quest Diagnostics' decision to discontinue the operations of its Nichols Institute Diagnostics (NID) segment.

The estimated pretax charges have been revised downwards from an initial estimate of up to $45 million to a new range of $32 million to $39 million. The associated cash expenditures have also been revised from up to $35 million to an estimated $20 million to $27 million.

The charges include costs for inventory write-offs and asset impairment ($12 million), employee termination benefits ($5-6 million), contract termination costs ($8-12 million), and expenses to support the wind-down of the business ($7-9 million).

No, approximately $7 million to $10 million of the charges are expected to be non-deductible for tax purposes, which will impact the company's net income.